Ads by Google
Pall Corporation's fourth quarter sales grew to $723.2 million, an 11.9% increase over the fourth quarter of fiscal 2007.
Diluted earnings per share (EPS) were $0.57, up from $0.13 a year earlier.
Net earnings were $69.9 million, compared to $16.8 million.
Pro forma EPS, excluding restructuring and other charges, were $0.61 versus last year's $0.46, an increase of 32.6%.
Within life sciences, biopharmaceuticals sales increased 4.6% in the quarter, and 10.8% for the full year.
The company says it will continue to win business for new drugs and factories as evidenced by the 41.1% increase in systems sales in the year.
It is also benefitting from increased production of biotechnology drugs and vaccines.
The recent acquisition of GeneSystems further expands Pall's capabilities in the biopharmaceuticals, medical, food and water safety markets.
Diluted earnings per share (EPS) were $0.57, up from $0.13 a year earlier.
Net earnings were $69.9 million, compared to $16.8 million.
Pro forma EPS, excluding restructuring and other charges, were $0.61 versus last year's $0.46, an increase of 32.6%.
Within life sciences, biopharmaceuticals sales increased 4.6% in the quarter, and 10.8% for the full year.
The company says it will continue to win business for new drugs and factories as evidenced by the 41.1% increase in systems sales in the year.
It is also benefitting from increased production of biotechnology drugs and vaccines.
The recent acquisition of GeneSystems further expands Pall's capabilities in the biopharmaceuticals, medical, food and water safety markets.
Del.icio.us |
